The earnings call presents a mixed picture with strong growth in recurring revenue streams, new product launches, and U.S. revenue growth. However, these positives are balanced by overall revenue decline, significant drops in EMEA and APAC sales, lower gross profits, and increased operational losses, indicating challenges in the current market environment.

Company Guidance -

Q3 2025

During the Cytek Biosciences Second Quarter 2025 Earnings Conference Call, the company provided detailed guidance on their financial performance and strategic outlook. The second quarter revenue was reported at $45.6 million, marking a decrease of 2.2% compared to the same period in 2024. Despite lower product revenues in EMEA and APAC, there was an 18% growth in service revenue globally, along with a notable 7% increase in total U.S. revenue. Recurring revenue, which includes service and reagent sales, grew by 16%, comprising 32% of the trailing 12-month sales. The company also highlighted a 3% increase in FSP unit volume, particularly driven by their Aurora Analyzers. Looking ahead, Cytek narrowed its full-year 2025 revenue guidance to between $196 and $205 million, reflecting a range from a 2% decrease to a 2% increase over 2024, factoring in current currency exchange rates. Additionally, Cytek emphasized their strategic focus on expanding their installed base and launching new products, such as the Cytek Aurora Evo system, to strengthen their market leadership and drive future growth.

Strong Recurring Revenue Growth

Service and Reagent revenue each increased by 18% versus the second quarter of 2024, contributing significantly to recurring revenue, which reached 32% of trailing 12-month sales, growing 16% versus last year.

Aurora Analyzers Drive FSP Growth

3% growth in FSP unit volume was observed in the second quarter, led by Aurora Analyzers, with particular strength in the U.S. showing 10% year-over-year growth.

New Product Launches

The launch of the Cytek Aurora Evo system and Micro Muse are expected to drive market leadership, with Aurora Evo setting a new standard in full spectral flow cytometry.

U.S. Revenue Growth

Total U.S. revenue was up 7% over the second quarter of 2024, driven by service and reagents.

Reagent Revenue Achievement

Reagent revenue achieved its highest ever quarterly revenues in Q2, representing 18% growth over the prior year quarter.

Cytek Biosciences (CTKB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CTKB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.02 / -	0.063	―	―	―
Aug 06, 2025	2025 (Q2)	-0.05 / -0.04	-0.026	-53.85% (-0.01)	―
May 08, 2025	2025 (Q1)	-0.03 / -0.09	-0.007	-1185.71% (-0.08)	―
Feb 27, 2025	2024 (Q4)	0.10 / 0.12	0.09	34.44% (+0.03)	―
Nov 05, 2024	2024 (Q3)	0.01 / 0.06	-0.008	887.50% (+0.07)	―
Aug 06, 2024	2024 (Q2)	>-0.01 / -0.03	0.014	-285.71% (-0.04)	―
May 08, 2024	2024 (Q1)	-0.03 / >-0.01	0	―	―
Feb 28, 2024	2023 (Q4)	0.03 / 0.09	0.06	50.00% (+0.03)	―
Nov 07, 2023	2023 (Q3)	0.02 / >-0.01	0.04	-120.00% (-0.05)	―
Aug 08, 2023	2023 (Q2)	0.01 / 0.01	0.03	-53.33% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CTKB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$3.89	$4.11	+5.66%
May 08, 2025	$3.79	$2.92	-22.96%
Feb 27, 2025	$4.81	$4.49	-6.65%
Nov 05, 2024	$5.44	$7.40	+36.03%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cytek Biosciences (CTKB) report earnings?

Cytek Biosciences (CTKB) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Cytek Biosciences (CTKB) earnings time?

Cytek Biosciences (CTKB) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CTKB EPS forecast?

CTKB EPS forecast for the fiscal quarter 2025 (Q3) is -0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing